NCT06816823
CAR-NK Cells (CL-NK-001) in Pancreatic Cancer
Recruiting · Phase 1 · Changhai Hospital · registry updated 2025-06-04
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
This is a single-center, open-label, first-in-human, dose-escalation study in patients with pancreatic cancer.
Inclusion
- Aged 18-70 years;
- Locally advanced, metastatic, or recurrent pancreatic cancer, with immunohistochemical detection of eGR1 (membrane positive tumor cell rate \>40% and expression intensity ≥2+), who have failed, been intolerant to or reject standard treatment;
- At least 1 measurable lesion according to RECIST 1.1;
- Have not received anti-tumor treatment for at least 4 weeks;
- ECOG performance status of 0-2;
- Estimated life expectancy more than 12 weeks;
Exclusion
- Evidence of central nervous system involvement;
- Have received adoptive cell therapy;
- Patients with any uncontrolled active infection, including but not limited to: HBV, HCV, HIV, or treponema pallidum serology positive;
- Vaccinated with a live attenuated vaccine within 3 months;
- History of immunodeficiency;
- Active autoimmune disease;